Illumiscreen Non-Invasive Prenatal Screening – Important Information
Illumiscreen Non-Invasive Prenatal Screening Limitations of the test This test is designed to screen for chromosome aneuploidies and is validated for chromosomes 21, 18, 13 and for fetal gender. The test is validated for singleton and twin pregnancies with gestational age of at least 10 weeks 0 days, as estimated by last menstrual period, crown … Continue reading “Illumiscreen Non-Invasive Prenatal Screening – Important Information”
COVID Can’t Stop Us
Learn how we assisted with the COVID-19 testing capacity with the Ministry of Health.
NIPT: cost effective, first line screening for all pregnant women
The Illumiscreen prenatal test maximises cost-effectiveness with the lowest failure rate.
Highlights From ACOG-SMFM
What is new in DNA screening?
Technology of Choice
Data shows Illumina next-generation sequencing is the NIPT technology of choice.
Accurate and Reliable Testing
Accurate and Reliable Testing The Illumiscreen prenatal test uses proven NGS technology to provide accurate NIPT results with the lowest failure rate What is test failure? For noninvasive prenatal testing (NIPT), test failure indicates that no call for chromosomal status can be made. This is an important factor in the reliability and clinical utility of … Continue reading “Accurate and Reliable Testing”